Red blood cell (RBC) transfusion is a life-saving therapeutic tool. However, a major complication in transfusion recipients is the generation of antibodies against non-ABO alloantigens on donor RBCs, potentially resulting in hemolysis and renal failure. Long-lived antibody responses typically require CD4(+) T cell help and, in murine transfusion models, alloimmunization requires a spleen. Yet, it is not known how RBC-derived antigens are presented to naive T cells in the spleen. We sought to answer whether splenic dendritic cells (DCs) were essential for T cell priming to RBC alloantigens. Transient deletion of conventional DCs at the time of transfusion or splenic DC preactivation before RBC transfusion abrogated T and B cell responses to allogeneic RBCs, even though transfused RBCs persisted in the circulation for weeks. Although all splenic DCs phagocytosed RBCs and activated RBC-specific CD4(+) T cells in vitro, only bridging channel 33D1(+) DCs were required for alloimmunization in vivo. In contrast, deletion of XCR1(+)CD8(+) DCs did not alter the immune response to RBCs. Our work suggests that blocking the function of one DC subset during a narrow window of time during RBC transfusion could potentially prevent the detrimental immune response that occurs in patients who require lifelong RBC transfusion support.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886363 | PMC |
http://dx.doi.org/10.1084/jem.20151720 | DOI Listing |
Asian J Transfus Sci
November 2023
Department of Transfusion Medicine, Tata Medical Center, Kolkata, West Bengal, India.
Noise in the immunohematological investigations can be described as a false reactivity of red blood cells (RBCs) in serologic testing that is not related to the interaction of RBC antigens and antibodies that the test system is intended to detect. These false-positive reactions can cause confusion during the cross-matching and RBC antibody screening and may result in delays in patient transfusion. Although these antibodies are predominantly clinically insignificant, proper laboratory work-up is indicated to avoid misidentification of a clinically significant antibody as a noise.
View Article and Find Full Text PDFAsian J Transfus Sci
September 2022
Department of Oncopathology, Malabar Cancer Centre, Thalassery, Kerala, India.
Background: Transfusion is an integral part of supportive care in patients undergoing aggressive chemotherapy for acute myeloid leukemia (AML). As transfusion induces immune modulation, the objective of the study was to assess whether the intensity of red blood cell (RBC) and platelet (PLT) transfusion during induction chemotherapy influences complete remission (CR) and overall survival (OS) in newly diagnosed AML patients.
Methods: Details of the number of RBC units and PLT events transfused from diagnosis till completion of induction chemotherapy were collected.
Asian J Transfus Sci
December 2022
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Background: Thalassemia is one of the most common congenital hemoglobinopathies globally. Regular red blood cell (RBC) transfusion is of paramount importance in the treatment of thalassemia patients. However, this practice increases the risk of alloimmunization.
View Article and Find Full Text PDFAsian J Transfus Sci
December 2024
Department of Transfusion Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Background: The direct antiglobulin test (DAT) detects red blood cell (RBC) sensitivity to complement or IgG . The clinical disorders of hemolytic disease of the newborn, hemolytic transfusion reaction, and autoimmune and drug-induced hemolytic anemia are some examples of those that can cause coating of RBCs with antibodies or complement autoimmune hemolytic anemia (AIHA). Rarely, DAT is positive in nonimmune-mediated hemolytic anemias as well.
View Article and Find Full Text PDFAsian J Transfus Sci
May 2023
Centre for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Background: Transfusion support is vital for the management of patients with hepatobiliary disease. Repeated blood transfusions increase the risk of alloimmunization, i.e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!